We Write Code Adopts WWC as Public-Facing Name, Reorganizes Around Six Services and Puts AI at the Center Dataiku Welcomes Shaun McGirr, AI Evangelist to Help Customers Maximise Value From AI
Leading AI unicorn welcomes industry-recognised senior data scientist to its U.K. team LONDON, 16 March,…
ViaDerma, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free
The Company expects to completely self-fund all operations going forward LOS ANGELES, March 16, 2021…
Vistin Pharma ASA: Mandatory notification of trade
Intertrade Shipping AS har mandag 15. mars kjøpt 1.500.000 aksjer i Vistin Pharma ASA forNOK 23,60…
Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination
Press Release 16 March 2021 Immunicum AB (publ) Announces Updated Executive Management Team After Business…
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in…
Innate Pharma announces conference call and webcast for Full Year 2020 financial results
Marseille, March 16, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN:…
Innate Pharma Announces Conference Call and Webcast for Full Year 2020 Financial Results
MARSEILLE, France, March 16, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH –…
New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
SUNFISH Part 2 study population includes broad range of ages and disease severities, representing a…
NOTICE TO DISREGARD — Avicanna Inc.
TORONTO, March 15, 2021 (GLOBE NEWSWIRE) — We are advised by Avicanna Inc. that journalists and…
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive…
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
– Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million –…
Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Daix (France), March 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical…
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint…
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim…
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a…
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
MIAMI, March 15, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ:LGVN) (“Longeveron” or the “Company”), a…
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020
Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 RANCHO…
Motus GI Announces First Patient Enrolled in a Pilot Study Using the Pure-Vu® System for Patients with Lower GI Bleeding Being Conducted by a Leading U.S. Medical Center
FORT LAUDERDALE, Fla., March 15, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus
Agreement leverages Fulgent’s Next Generation Sequencing (“NGS”) capabilities for genomic sequencing to aid in ongoing…
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion…